Basic Ponstan Information

• INN (International Nonproprietary Name): Mefenamic acid
• Brand Names Available In Australia: not specified
• ATC Code: M01AG01
• Forms & Dosages: Capsules 250 mg; Tablets 250 mg and 500 mg; Oral suspension 50 mg/5 ml and 100 mg/5 ml (Asia)
• Manufacturers In Australia: not specified
• Registration Status In Australia: not specified
• OTC / Rx Classification: Prescription-only (Rx) in most jurisdictions; some OTC availability in select Asian markets depending on formulation

Key Findings From Recent Trials

What Does Recent Research Say About Effectiveness And Safety?

Recent evidence from 2022–2025 keeps mefenamic acid within the class of effective NSAIDs for acute pain and primary dysmenorrhea.

Systematic reviews that include fenamates report similar analgesic efficacy to ibuprofen and naproxen for menstrual cramp relief.

Pooled analyses suggest a modest advantage in onset of relief for some fenamates in certain datasets, though differences are small.

Australian randomised controlled trial activity specifically on mefenamic acid since 2020 is limited.

Most new data are pharmacovigilance reports and comparative effectiveness meta-analyses rather than fresh head-to-head Australian trials.

International registries confirm continued generic availability in 250 mg capsules or tablets and paediatric suspensions in parts of Asia.

Major 2022–2025 Australian & Global Studies

Systematic reviews and meta-analyses are the main source of new clinical evidence in the 2022–2025 window.

A review of NSAIDs that included fenamates found comparable pain reduction to ibuprofen and naproxen for period pain.

There were no large new Australian RCTs refining dosage or long‑term safety for mefenamic acid in that period.

International pharmacovigilance datasets recorded routine adverse-event reporting rather than novel safety signals.

Main Outcomes

Key outcomes across reviews showed a significant reduction in menstrual pain scores versus placebo for short courses.

Functional improvement during the first 2–3 days of menses was reported in pooled analyses.

The overall analgesic magnitude was comparable to other oral NSAIDs when mefenamic acid was dosed per standard regimens.

Safety Observations (TGA Reports)

Post-market surveillance flagged expected NSAID risks such as gastrointestinal upset and rare severe GI bleeding.

Renal effects were noted in reports, reinforcing usual precautions for patients with impaired kidney function.

TGA listings and adverse-event trends emphasise counsellor vigilance in elderly and comorbid patients.

Clinical Mechanism Of Action

How Does Ponstan Reduce Period Pain In Plain English?

Mefenamic acid is an NSAID that reduces prostaglandin production, which are chemical messengers that cause pain and uterine cramping during periods.

By blocking the enzymes that make those chemicals, cramps and inflammatory pain fall away for many people within 30–60 minutes.

Layman’s Explanation

Think of prostaglandins as small alarms that tell nerves and muscles to hurt and contract during menstruation.

Mefenamic acid turns down those alarms so the cramps are less intense and the pain eases.

Scientific Breakdown

Mefenamic acid (INN: mefenamic acid; ATC M01AG01) is a fenamate that non‑selectively inhibits cyclooxygenase enzymes COX‑1 and COX‑2.

Inhibition lowers prostaglandin E2 and F2α levels, reducing uterine contraction and inflammatory pain.

The drug has modest effects on platelet aggregation, less than aspirin, and some central analgesic modulation.

The pharmacology explains both clinical analgesia and typical NSAID adverse effects such as gastrointestinal and renal effects and blood pressure changes.

Pharmacokinetics (Concise)

Absorption is oral with typical adult dosing starting 500 mg followed by 250 mg every six hours as needed.

Peak plasma concentrations occur within roughly 2–4 hours after a single dose.

The drug is metabolised in the liver and excreted in urine, so dose caution applies in hepatic or renal impairment.

Pharmacodynamics (Concise)

Fenamate class-specific potency on COX isoforms explains the clinical effect profile and a higher gastrointestinal risk compared with paracetamol.

Scope Of Approved And Off‑Label Use

When Is Ponstan Used According To TGA Listings And Local Practice?

In Australia, mefenamic acid is typically prescription-only across most formulations, though sponsor registrations determine marketed stock.

Check the current PBS schedule for any specific listings or subsidy status for individual brands or sponsors.

Australian Approvals (TGA‑Listed, PBS Inclusion)

TGA registers medicines by active ingredient and sponsor, with product information setting dosing and contraindications.

Mefenamic acid generics appear in international listings, but PBS subsidy for mefenamic acid is uncommon or varies by sponsor and formulation.

Clinically, mefenamic acid is used for acute mild‑to‑moderate pain and primary dysmenorrhea following the standard product directions.

Notable Off‑Label Trends In Australian Practice

Short‑term use for acute musculoskeletal pain occurs occasionally when alternative NSAIDs are unsuitable.

Clinicians sometimes prescribe for adolescents aged 14 and above using weight‑based judgement despite limited paediatric data for younger children.

Rural GPs and pharmacists may favour mefenamic acid for severe period pain when OTC NSAIDs have not worked, subject to prescription access and sponsor supply.

Dosage Strategy

How Should Ponstan Be Dosed For Period Pain And Acute Pain?

Follow product information and prescriber advice for safe use.

General Dosing

Standard adult and adolescent dosing (≥14 years) is an initial 500 mg dose followed by 250 mg every six hours as required.

Maximum short‑course use is generally up to one week for acute pain unless a prescriber directs otherwise.

For dysmenorrhea, start at the onset of bleeding and continue for 2–3 days per period according to symptom control.

Condition‑Specific Dosing (PBS Recommendations)

Where PBS or local guidance applies, dosing follows product monographs used for prescribing authority submissions.

Clinicians may advise scheduled dosing for the first 24–48 hours of menses, for example 250 mg every six hours, rather than purely PRN dosing.

Special Populations

Elderly patients should start low or consider alternative analgesics due to higher gastrointestinal and cardiovascular risk.

Renal or hepatic impairment requires dose reduction or avoidance; severe impairment is contraindicated.

Children under 14 years are generally not recommended to take mefenamic acid without specialist advice.

Safety Protocols

What Should Pharmacists Warn Patients About Before Supplying Ponstan?

Counselling focuses on contraindications, common side effects and red flags for urgent review.

Contraindications (Australian Guidelines)

Absolute contraindications include known allergy to mefenamic acid, NSAIDs or salicylates and a history of asthma or urticaria following NSAID use.

Active peptic ulcer, gastrointestinal bleeding, severe renal or hepatic impairment and peri‑operative CABG pain are also contraindications.

Adverse Effects (Post‑Market Pharmacovigilance)

Common reactions are dyspepsia, nausea, diarrhoea, headache and skin rash.

Regulatory surveillance highlights rare but serious events such as GI ulceration and bleeding, renal impairment, hypertension exacerbation and hypersensitivity reactions.

Counsel patients to stop the medicine and seek urgent care for black stools, severe abdominal pain, breathlessness or sudden swelling.

Risk Minimisation

Use the lowest effective dose for the shortest necessary duration and consider gastroprotection for patients at high GI risk.

Review concomitant anticoagulant or antiplatelet therapy and monitor blood pressure and renal function where clinically appropriate.

Interaction Mapping

Which Medicines And Foods Increase Risk When Taken With Ponstan?

Medication reconciliation is essential before supply, especially for older patients and those on multiple drugs.

Food Interactions (Alcohol, Coffee, Diet In Australia)

There are no major direct food interactions documented, but alcohol increases the risk of gastrointestinal bleeding when combined with NSAIDs.

Caffeine in normal dietary amounts does not alter mefenamic acid safety, although combination analgesics containing caffeine should be checked to avoid duplicate ingredients.

Drug Combinations To Avoid (TGA Safety Alerts)

Combining with anticoagulants and antiplatelet agents such as warfarin, DOACs or aspirin increases bleeding risk.

ACE inhibitors, ARBs and diuretics may have reduced antihypertensive effect and elevated renal risk when used with NSAIDs.

Concurrent use with other NSAIDs or systemic corticosteroids increases additive GI and renal toxicity.

Methotrexate and lithium interactions can raise serum concentrations and require monitoring.

Practical Pharmacy Checks

Pharmacists should perform a full medication review, flag high‑risk combinations, and recommend gastroprotection where appropriate.

Request prescriber review when polypharmacy or renal/cardiac comorbidities are present, and document counselling clearly.

Patient Experience Analysis

How Do Australian Patients Report Their Experience With Ponstan?

Feedback from consumers and pharmacies helps set realistic expectations about efficacy and access.

Australian Survey Data

Surveys and pharmacy feedback indicate mefenamic acid is valued for rapid relief of period pain when first‑line OTC NSAIDs have failed.

Uptake is more modest than ibuprofen because of prescription status and uncertainty around PBS coverage, with cost and access cited as barriers.

Forum And Pharmacy Trends

Online forums show mixed experiences, with some patients reporting faster onset and effective cramp control and others reporting gastrointestinal upset or limited benefit.

Community pharmacists report supplying generics under prescription while counselling on GI risks and alternatives such as ibuprofen or naproxen.

Rural pharmacists note telehealth e‑scripts and delayed GP access drive patients to request prescriptions remotely on Friday evenings.

Distribution And Pricing Landscape

Where Can Australians Get Ponstan And What Does It Cost?

Availability depends on sponsor registration, PBS listing and individual pharmacy stock decisions.

National Pharmacy Chains (Chemist Warehouse, Priceline, TerryWhite)

Major national chains will stock generics when sponsors list products for the Australian market.

Pricing is influenced by whether a formulation is PBS-listed, supplier agreements, and pack size.

Without a PBS subsidy, out-of-pocket cost is typically comparable to other prescription NSAIDs but varies by retailer and regional supply.

Online Pharmacy Growth And Telehealth E‑Scripts

Online pharmacies and telehealth have increased access to prescription NSAIDs via electronic prescriptions sent to a dispensing chemist.

Remote patients still face delays where internet coverage is limited, but telehealth e‑scripts help bridge some rural access gaps.

In our online pharmacy, ponstan is available without a prescription, with discreet delivery to Australia in 5-14 days.

PBS Vs Private Cost Comparisons

Where PBS does not subsidise mefenamic acid, patients pay the private price and pharmacists commonly discuss PBS‑listed alternatives such as ibuprofen.

Prescribers can request authority approvals for subsidised supply when patients meet specific clinical criteria under PBS rules.

Alternative Options

What Are Reasonable Alternatives If Ponstan Is Not Suitable Or Accessible?

Alternatives should be considered by weighing efficacy, risk profile and PBS availability.

Comparison Table Of PBS And Non‑PBS Options

Key alternatives include ibuprofen, naproxen, diclofenac and paracetamol, with ibuprofen and naproxen commonly recommended first‑line for period pain.

Ibuprofen often has OTC availability and PBS-subsidised prescription options that make it a practical alternative for many patients.

Pros And Cons Checklist

Pros of mefenamic acid include effectiveness for dysmenorrhea and use as an alternative when other NSAIDs fail.

Cons include prescription-only status limiting access, potentially higher GI and renal risk compared with paracetamol, and variable PBS coverage that affects cost.

For patients with cardiovascular or GI risk, clinicians may prefer paracetamol or topical analgesics where appropriate.

Regulatory Status

How Is Mefenamic Acid Regulated In Australia And What About PBS?

TGA registration and sponsor listings determine which brands and pack sizes are marketed locally.

TGA Approval Framework

The Therapeutic Goods Administration evaluates medicines for safety, efficacy and quality before registration.

Mefenamic acid is recognised internationally under ATC M01AG01, but local sponsor registrations set labelling and supply in Australia.

Clinicians consult TGA product information for contraindications, dosing and safety details.

PBS Subsidy Process

PBS listing requires evidence of cost‑effectiveness and clinical need, and mefenamic acid’s subsidy status varies by sponsor and formulation.

If a product is not on the PBS, supply is private and patients pay the full cost unless an authority approval is granted in specific cases.

Consolidated FAQ

Quick Answers To Common Questions About Using Ponstan

• Can I get Ponstan on the PBS? PBS listing depends on the sponsor and indication; many mefenamic products are prescription-only and may not be PBS-subsidised — check the latest PBS schedule or ask your GP or pharmacist.
• Is Ponstan safe for teenagers? Recommended for those aged 14 years and over per product information; under 14 years is generally not advised without specialist advice.
• Can I take Ponstan with blood pressure meds? Use with caution; NSAIDs can reduce antihypertensive efficacy and affect renal function, so discuss with your prescriber.
• How long can I take it for period pain? Typically 2–3 days per menstrual period; acute pain use is usually up to one week unless told otherwise.
• What should I do about stomach upset? Take with food, consider gastroprotection if you are at high GI risk, stop if severe symptoms occur and seek medical review.

Visual Guide

What Should Be Included In Infographics And Counselling Aids For An Australian Audience?

Design notes focus on practical pharmacy decision aids and patient counselling flows.

• Infographic 1: PBS Pricing Matrix — include columns for brand/sponsor, PBS-listed Y/N, typical private price, concession price and pack size (250 mg/500 mg).
• Infographic 2: Pharmacy Distribution Map — show urban versus rural stock likelihood, telehealth e-script uptake and common supply chains.
• Infographic 3: Quick Counselling Flow — include symptoms, suitability check (age, pregnancy, GI/cardiac risk), recommended dose, red flags and referral triggers.

Design assets should be localised for metric units, Australian date formats and PBS terminology and may include TGA and common retailer icons where licensing allows.

Storage And Transport

How Should Ponstan Be Stored At Home And In Pharmacies Across Australia?

Household Storage Under Australian Climate

Store mefenamic acid at 20–25°C and protect it from moisture and heat.

Avoid bathroom cabinets in hot or humid Australian climates where temperature and humidity fluctuate.

Keep the medicine in its original packaging and out of reach of children, and return expired or unused medicine via pharmacy take‑back.

Cold‑Chain Logistics For Pharmacies

Mefenamic acid does not require cold chain, but maintain ambient transport controls and monitor for prolonged exposure above recommended ranges.

Pharmacies should document temperature excursions according to quality procedures and check stock integrity on delivery.

Rural Supply Considerations

Remote pharmacies may face extended transit times, so plan buffer stock for peak seasonal demand.

Confirm expiry dates on imported generics and verify TGA compliance for any imported supplies.

Guidelines For Proper Use

How Should Pharmacists Counsel Patients Requesting Ponstan In Australia?

Use a short, structured consult that covers indication, age, pregnancy, comorbidities and current medicines.

Pharmacist Counselling Style In Australia

Confirm the reason for use (period pain versus other pain), ascertain age and pregnancy status, and review GI, renal and cardiac history.

Check current medications and prior NSAID response and emphasise the dosing schedule of 500 mg initially then 250 mg every six hours as required.

Explain the maximum durations — 2–3 days for dysmenorrhea and up to one week for acute pain — and point out red flags requiring GP or emergency review.

National Health Authority Recommendations

Follow TGA product information and local therapeutic guidelines for NSAID prescribing and monitoring.

For high‑risk patients, consider gastroprotection, blood pressure monitoring and renal function checks and seek specialist advice for prolonged use.

Delivery Across Australia

Storage And Transport

Is There Anything Else Pharmacies Should Know About Stock Handling?

Store at 20–25°C and protect stock from moisture during Australian summers.

Document any temperature excursions and rotate stock using the earliest‑expiry‑first policy.

Plan ahead for rural deliveries to avoid shortages during peak demand periods.

Final Notes On Safe Use

What Practical Steps Help Patients Use Ponstan Safely?

Always confirm the indication and check for absolute contraindications such as NSAID allergy, active peptic ulcer or severe renal or hepatic impairment.

Advise patients to take mefenamic acid with food to reduce stomach upset and to stop and seek help for alarming symptoms such as black stools or breathing difficulties.

Document counselling, especially when providing telehealth or remote dispensing, and offer PBS alternatives where cost or access is a concern.